Baidu
Deal focus: Gitee aspires to be more than China’s Github
FutureX Capital got onto Gitee’s shareholder register by suggesting a separation from Baidu. Now, FutureX is backing the company to leverage its status as China’s dominant open-source software player
China's GitHub substitute raises $107m
Gitee, a China-based open-source platform regarded as a domestic substitute for GitHub, has raised an extended Series B of CNY 775m (USD 107m) led by FutureX Capital.
Baidu launches $145m China AI fund
China-based technology giant Baidu has launched an artificial intelligence (AI) fund of CNY 1bn (USD 145m) that will focus on generative AI companies.
VC investors primed for exit with China Youzan reorganisation
Hillhouse Capital and Matrix Partners China are set for liquidity events after China Youzan, an e-commerce software-as-a-service (SaaS) business listed in Hong Kong, agreed to take full control of its key subsidiary for HKD 2.6bn (USD 334.5m).
Hesai gains 11% on debut after $190m US offering
Hesai Technology, a China-based developer of sensors used in autonomous driving, traded up on debut after completing the largest US IPO by a Chinese company since Didi in 2021.
AI: Asia awakens to ChatGPT
ChatGPT has sent shockwaves through the technology sector globally. Asia is no exception as investors look for ways to leverage the platform and China contemplates a standard of its own
China LiDAR specialist Hesai aims for US IPO
Hesai Technology, a China-based developer of sensors used in autonomous driving, is targeting a US listing. Its investors include Lightspeed China Partners, Baidu, Bosch, and Xiaomi.
China-linked EcarX, Lanvin complete SPAC mergers
EcarX, a smart mobility solutions provider backed by Chinese automaker Geely Auto Group, and Lanvin Group, a global luxury fashion platform established by Fosun Group, both completed mergers with US-listed special purpose acquisition companies (SPACs).
Baidu-backed autonomous truck developer raises $67m
DeepWay, an intelligent driving solutions provider for trucks established by Baidu, has raised a Series A round of CNY 460m (USD 67m) led by Qiming Venture Partners.
Med-Fine leads Series A for China's Degron Therapeutics
US and China-based biotech player Degron Therapeutics has closed a USD 22m Series A round led by Med-Fine Capital.
China biotech player GenFleet raises $75m
GenFleet Therapeutics, a Chinese biotech developer focused on oncology and immunology, has secured a USD 75m Series C round led by Huagai Capital.
China's Broncus raises $215m in IPO, struggles on HK debut
Broncus Holding Corporation, a China-based manufacturer of medical devices used to treat lung diseases, plunged 12.8% on its Hong Kong trading debut following a HK$1.67 billion ($215 million) IPO.
China's Baidu Ventures closes $400m fund
Baidu Ventures (BV), a venture capital firm established by Chinese internet giant Baidu, has raised $400 million for its third US dollar-denominated fund.
China AI drug developer BioMap raises $100m
GGV Capital has led a $100 million Series A round for BioMap, a China-based biological computing platform. It marks the first time the company has sought external funding.
China DNA sequencing start-up gets $116m Series C
Chinese next-generation sequencing (NGS) player Geneplus Technology has raised a RMB750 million ($116 million) Series C round led by China Construction Bank’s venture unit CCB International.
Warburg Pincus leads Series C for China AI drug developer
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.
China's Nutshell Therapeutics raises $20m
Nutshell Therapeutics, a Chinese drug developer, has raised a $20 million Series A round led by Matrix Partners China.
Chinese pharmaceutical platform Yaoshibang raises $270m
Chinese B2B pharmaceutical trading platform Yaoshibang has raised $270 million from Guangdong Pearl River Investment, Baidu, Sunshine Insurance, Green Pine Capital Partners, Guangzhou government-backed S Fund, and an undisclosed sovereign wealth fund.
China gene sequencing company raises $63m
QitanTech, a gene sequencing start-up also known as Qitan Technology, has raised a RMB400 million ($63 million) Series B round led by Hillhouse Capital and a VC arm of CDH Investments.
China's Zhihu completes $522m IPO, endures volatile debut
Chinese question-and-answer platform Zhihu endured a difficult New York Stock Exchange debut, closing at a 10.5% discount to its IPO price on a day when US-listed Chinese stocks fluctuated wildly.
China regulation: Taming the giants
Recent regulatory reforms suggest that China will not let the growth of large technology companies go unchecked. The implications could be far-reaching, not least for VC investors and start-ups
China healthtech player gets $100m Series C extension
Weimai, a Chinese healthcare-focused big data platform that primarily serves hospitals and clinics in lower-tier cities, has raised $100 million in an extended Series C round led by Baidu Capital.